Arsenite decreases CYP3A4 and RXRα in primary human hepatocytes

被引:29
|
作者
Noreault, TL
Kostrubsky, VE
Wood, SG
Nichols, RC
Strom, SC
Trask, HW
Wrighton, SA
Evans, RM
Jacobs, JM
Sinclair, PR
Sinclair, JF [1 ]
机构
[1] Vet Adm Med Ctr, White River Jct, VT 05009 USA
[2] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol Toxicol, Hanover, NH 03756 USA
[3] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Microbiol Immunol, Hanover, NH 03756 USA
[4] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA
[5] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03756 USA
[6] Pfizer, Dept Safety Sci, Ann Arbor, MI USA
[7] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA
[8] Lilly Res Labs, Indianapolis, IN USA
[9] Salk Inst Biol Studies, Howard Hughes Med Inst, San Diego, CA USA
关键词
D O I
10.1124/dmd.105.003954
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Arsenic is a naturally occurring, worldwide contaminant implicated in numerous pathological conditions in humans, including cancer and several forms of liver disease. One of the contributing factors to these disorders may be the alteration of cytochrome P450 ( P450) levels by arsenic. P450s are involved in the oxidative metabolism and elimination of numerous toxic chemicals. CYP3A4, a major P450 in humans, is involved in the metabolism of half of all currently used drugs. Acute exposure to arsenite decreases the induction of CYP1A1/2 proteins and activities in cultured human hepatocytes, as well as CYP3A23 in cultured rat hepatocytes. Here, in primary cultures of human hepatocytes, we assessed the effects of acute arsenite exposure on CYP3A4 and several transcription factors involved in CYP3A4 expression. The concentrations of arsenite used in these studies were nontoxic to the hepatocytes and failed to elicit an oxidative response. Treatment with arsenite in the presence of CYP3A4 inducers, rifampicin (Rif) or phenobarbital, caused major decreases in CYP3A4 mRNA, protein, and activity. In addition, the levels of CYP3A4 in untreated cells were decreased following arsenite treatment. Transcription of the CYP3A4 gene is primarily regulated by heterodimers of the retinoid X receptor alpha (RXR alpha) and the pregnane X receptor (PXR). We found that arsenite failed to affect expression of PXR or the transcription factor Sp1, yet caused a significant decrease in PXR responsiveness to Rif. Arsenite caused a large decrease in nuclear RXR alpha protein and, to a lesser extent, RXR alpha mRNA. These results suggest that arsenite inhibits both untreated and induced CYP3A4 transcription in primary human hepatocytes by decreasing the activity of PXR, as well as expression of the nuclear receptor RXR alpha.
引用
收藏
页码:993 / 1003
页数:11
相关论文
共 50 条
  • [41] Investigation of Orlistat effects on PXR activation and CYP3A4 expression in primary human hepatocytes and human intestinal LS174T cells
    Novotna, Aneta
    Doricakova, Aneta
    Vrzal, Radim
    Maurel, Patrick
    Pavek, Petr
    Dvorak, Zdenek
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 41 (02) : 276 - 280
  • [42] Expression of CYP3A4 in human breast tumors
    Coban, T
    Kapucuoglu, N
    Raunio, H
    Pelkonen, O
    Edwards, RJ
    Boobis, AR
    Iscan, M
    DRUG METABOLISM REVIEWS, 2004, 36 : 92 - 92
  • [43] Ligand Diversity of Human and Chimpanzee CYP3A4: Activation of Human CYP3A4 by Lithocholic Acid Results from Positive Selection
    Kumar, Santosh
    Qiu, Huan
    Oezguen, Numan
    Herlyn, Holger
    Halpert, James R.
    Wojnowski, Leszek
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (06) : 1328 - 1333
  • [44] Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin
    Hesse, LM
    Sakai, Y
    Vishnuvardhan, D
    Li, AP
    von Moltke, LL
    Greenblatt, DJ
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (09) : 1229 - 1239
  • [45] Comparative Study of Culture Conditions for Maintaining CYP3A4 and ATP-Binding Cassette Transporters Activity in Primary Cultured Human Hepatocytes
    Takeba, Yuko
    Matsumoto, Naoki
    Takenoshita-Nakaya, Sachiko
    Harimoto, Yoshie
    Kumai, Toshio
    Kinoshita, Yuichi
    Nakano, Hiroshi
    Ohtsubo, Takehito
    Kobayashi, Shinichi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (04) : 516 - 524
  • [46] Role of the calpain pathway in arsenite-mediated decreases in CYP3A in cultured rat hepatocytes.
    Noreault, TL
    Dwyer, B
    Nichols, R
    Trask, H
    Wrighton, S
    Sinclair, P
    Sinclair, J
    TOXICOLOGICAL SCIENCES, 2003, 72 : 16 - 17
  • [47] Selective expression of CYP3A5 and not CYP3A4 in human blood
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Thummel, KE
    Watkins, PB
    PHARMACOGENETICS, 1996, 6 (05): : 379 - 385
  • [48] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [49] EVALUATION OF TIME-DEPENDENT INHIBITION OF CYP3A4 IN PLATED AND SUSPENDEND HUMAN HEPATOCYTES BY MODEL INHIBITORS
    Zhang, J. George
    Thuy Ho
    Callendrello, Alanna L.
    Santone, Elizabeth A.
    Xiao, Deqing
    Stresser, David M.
    DRUG METABOLISM REVIEWS, 2014, 45 : 130 - 130
  • [50] DUAL ROLES OF NUCLEAR RECEPTOR LXRA IN THE CYP3A4 EXPRESSION IN HUMAN HEPATOCYTES AS A POSITIVE AND NEGATIVE REGULATOR
    Watanabe, Keisuke
    Yamazoe, Yasushi
    Sakurai, Kaori
    Yoshinari, Kouichi
    DRUG METABOLISM REVIEWS, 2014, 45 : 140 - 141